Global investment firm KKR and Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company, announced that KKR has agreed to acquire Biosynth Carbosynth from Armira and CEO Dr. Urs Spitz. Financial details of the transaction were not disclosed. Dr. Spitz and senior managers of the company will retain a significant ownership…